Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-12-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于公司筹划发行H股股票并在香港联合交易所有限公司上市相关事项的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1033 characters) regarding the company's plan to issue H shares and list on the Hong Kong Stock Exchange. It discusses board meeting approvals, regulatory requirements, and the uncertainty of the issuance and listing process. There are no financial statements or detailed financial data presented. The document serves as a notification of a capital raising plan and listing intention, not a full capital/financing update report. Given the short length and nature of the announcement, it fits best under Capital/Financing Update (CAP).
2024-12-15 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司归还前次暂时补充流动资金的闲置募集资金并继续使用部分闲置募集资金暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the use and management of idle raised funds by Maiwei (Shanghai) Biotechnology Co., Ltd. It discusses the company's compliance with regulatory requirements, the use of idle raised funds to temporarily supplement working capital, approvals by the board and supervisory committee, and the verification by the sponsor institution. The document references specific regulatory guidelines and includes financial figures related to the raised funds and their usage. It is not a brief announcement but a substantive report on the use of raised funds, including audit and supervisory opinions. This fits the category of a Capital/Financing Update (CAP), as it focuses on the management and use of capital raised through the IPO and subsequent fund usage plans and approvals.
2024-12-15 Chinese
迈威生物关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement from the company about the appointment of a new Vice General Manager (副总经理) and nomination of the same individual as a non-independent director candidate. It includes the individual's resume and details about the board meeting approving the appointment. There is no financial data, no report or presentation content, and the document is focused on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2024-12-15 Chinese
迈威生物关于归还前次暂时补充流动资金的闲置募集资金并继续使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the return and continued use of idle raised funds temporarily supplementing working capital. It includes details about the amount of funds, board and supervisory committee approvals, regulatory compliance references, and opinions from the supervisory board and sponsoring institutions. The document does not contain comprehensive financial statements or detailed financial performance data. It is primarily an update on the company's capital usage and financing activities related to raised funds. The document length is 3576 characters, which is relatively short and focused on a specific financing update rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-12-15 Chinese
迈威生物关于召开2024年半年度暨第三季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a performance explanation meeting (业绩说明会) for the 2024 half-year and third quarter results. It mentions that the company has already disclosed the half-year and third quarter reports on the Shanghai Stock Exchange website. The document provides details about the meeting time, location, participants, and how investors can participate and ask questions. It does not contain actual financial data or detailed financial statements but serves as a notice for an upcoming investor presentation event. According to the classification rules, such announcements about meetings to discuss financial results are classified as Investor Presentation (IP). The document length is short (1494 characters), and it is clearly an announcement of a meeting rather than the report itself or a transcript. Therefore, the correct classification is Investor Presentation (IP).
2024-11-20 Chinese
迈威生物关于变更部分募集资金专用账户并重新签订四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the change of certain special accounts for raised funds and the re-signing of a four-party supervision agreement. It details the background of the fundraising, the specific accounts involved, the new agreement terms, and includes opinions from the supervisory board and the sponsoring institution. The document does not contain financial statements or performance data but focuses on the management and regulatory compliance of fundraising accounts. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about capital management and compliance related to fundraising accounts. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 4717 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2024-10-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.